Key facts
- It has raised $6.8M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Tech Incubator Program for Startup, Enlight Ventures, Posco Investment, Y&Archer, BiiG WAVE — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for VSPharmTech
- ·The full record, as it builds
Funding rounds
No funding rounds for VSPharmTech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VSPharmTech
Developer of radiation sensitizer drugs designed to increase the efficacy of anticancer drugs. The company specializes in technology commercialization developed by domestic and overseas anticancer research groups and mechanism-driven synergy-equipped radiosensitizers that excel in low toxicity, enabling patients and the healthcare sector to undergo chemotherapy with safe and effective drugs and offer a safe treatment.
- Sector
- Healthcare
- HQ
- Daegu, South Korea
- Founded
- 2018
- Employees
- 17
- Website
- vspharmtech.com/
- Ownership
- Privately Held (backing)
VSPharmTech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VSPharmTech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VSPharmTech in its N-PORT filings yet. We sweep new filings monthly.